Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2019, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.
Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 12, 8, 2, 11, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
Introduction
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Development
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drug Profiles
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 8: Products under Development by Universities/Institutes, H2 2019
Table 9: Number of Products by Stage and Target, H2 2019
Table 10: Number of Products by Stage and Mechanism of Action, H2 2019
Table 11: Number of Products by Stage and Route of Administration, H2 2019
Table 12: Number of Products by Stage and Molecule Type, H2 2019
Table 13: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Alucent Medical Inc, H2 2019
Table 14: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AngioSoma Inc, H2 2019
Table 15: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AptaBio Therapeutics Inc, H2 2019
Table 16: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ARCA biopharma Inc, H2 2019
Table 17: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ArtGen Inc, H2 2019
Table 18: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athera Biotechnologies AB, H2 2019
Table 19: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys Inc, H2 2019
Table 20: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H2 2019
Table 21: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H2 2019
Table 22: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by BiogenCell Ltd, H2 2019
Table 23: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics Inc, H2 2019
Table 24: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celularity Inc, H2 2019
Table 25: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Constant Therapeutics LLC, H2 2019
Table 26: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals Inc, H2 2019
Table 27: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Exodos Life Sciences Limited Partnership, H2 2019
Table 28: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Foresee Pharmaceuticals Co Ltd, H2 2019
Table 29: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Helixmith Co Ltd, H2 2019
Table 30: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Hemostemix Inc, H2 2019
Table 31: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ID Pharma Co Ltd, H2 2019
Table 32: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Juventas Therapeutics Inc, H2 2019
Table 33: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by LipimetiX Development Inc, H2 2019
Table 34: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by MediaPharma SRL, H2 2019
Table 35: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nangiotx Inc, H2 2019
Table 36: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Novartis AG, H2 2019
Table 37: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Pharmosa Biopharm Inc, H2 2019
Table 38: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Polysan NTFF Ltd, H2 2019
Table 39: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H2 2019
Table 40: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp, H2 2019
Table 41: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Reven Pharmaceuticals Inc, H2 2019
Table 42: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sorrento Therapeutics Inc, H2 2019
Table 43: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies Inc, H2 2019
Table 44: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Symic Bio Inc, H2 2019
Table 45: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Vascugen Inc, H2 2019
Table 46: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by VESSL Therapeutics Ltd, H2 2019
Table 47: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H2 2019
Table 48: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 49: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H2 2019 (Contd..2), H2 2019
Table 50: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H2 2019
List of Figures
Figure 1: Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Top 10 Targets, H2 2019
Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019
